Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response...

Full description

Saved in:
Bibliographic Details
Published in:Blood advances 2019-03, Vol.3 (5), p.744-750
Main Authors: Tandon, Nidhi, Sidana, Surbhi, Rajkumar, S. Vincent, Gertz, Morie A., Buadi, Francis K., Lacy, Martha Q., Kapoor, Prashant, Gonsalves, Wilson I., Dispenzieri, Angela, Kourelis, Taxiarchis V., Warsame, Rahma, Dingli, David, Fonder, Amie L., Hayman, Suzanne R., Hobbs, Miriam A., Hwa, Yi Lisa, Kyle, Robert A., Leung, Nelson, Go, Ronald S., Lust, John A., Russell, Stephen J., Kumar, Shaji K.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Female
Humans
Lymphoid Neoplasia
Male
Middle Aged
Multiple Myeloma - diagnosis
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Multivariate Analysis
Remission Induction
Risk Factors
Survival Analysis
Time-to-Treatment
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with ≥VGPR and
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2018022806